VEGFR2 Human, His

KDR D1-7, sKDR D1-7, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. 

Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.

VEGFR2 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 987 amino acids (20-764a.a) and having a molecular mass of 110.5kDa (Molecular size on SDS-PAGE will appear at approximately 100-150kDa). VEGFR2 is fused to a 239 amino acids hIgG-His-tag at C-terminus & purified by proprietary chromatographic techniques.

Sf9, Baculovirus cells.

VEGFR2 solution (0.5mg/ml) contains Phosphate Buffered Saline (pH 7.4) and 10% glycerol.

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.

Greater than 90% as determined by SDS-PAGE.

ADPASVGLPS VSLDLPRLSI QKDILTIKAN TTLQITCRGQ RDLDWLWPNN QSGSEQRVEV TECSDGLFCK TLTIPKVIGN DTGAYKCFYR ETDLASVIYV YVQDYRSPFI ASVSDQHGVV YITENKNKTV VIPCLGSISN LNVSLCARYP EKRFVPDGNR ISWDSKKGFT IPSYMISYAG MVFCEAKIND ESYQSIMYIV VVVGYRIYDV VLSPSHGIEL SVGEKLVLNC TARTELNVGI DFNWEYPSSK HQHKKLVNRD LKTQSGSEMK KFLSTLTIDG VTRSDQGLYT CAASSGLMTK KNSTFVRVHE KPFVAFGSGM ESLVEATVGE RVRIPAKYLG YPPPEIKWYK NGIPLESNHT IKAGHVLTIM EVSERDTGNY TVILTNPISK EKQSHVVSLV VYVPPQIGEK SLISPVDSYQ YGTTQTLTCT VYAIPPPHHI HWYWQLEEEC ANEPSQAVSV TNPYPCEEWR SVEDFQGGNK IEVNKNQFAL IEGKNKTVST LVIQAANVSA LYKCEAVNKV GRGERVISFH VTRGPEITLQ PDMQPTEQES VSLWCTADRS TFENLTWYKL GPQPLPIHVG ELPTPVCKNL DTLWKLNATM FSNSTNDILI MELKNASLQD QGDYVCLAQD RKTKKRHCVV RQLTVLERVA PTITGNLENQ TTSIGESIEV SCTASGNPPP QIMWFKDNET LVEDSGIVLK DGNRNLTIRR VRKEDEGLYT CQACSVLGCA KVEAFFIIEG AQEKTNLELE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG KHHHHHH.

SDS